Insider filing · AKRO
Catriona Yale sold $2.7M of Akero Therapeutics (AKRO)
Executed Jan 27 2025, disclosed Jan 31 2025, 4 days later, against a two-business-day limit.
Value, as filed
$2.7M
49,074 sh across 3 lots
Executed
Jan 27 2025
the trade date, as filed
Disclosed
Jan 31 2025
4 days after the trade · past the deadline
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
CY
Catriona Yale
Chief Development Officer
profile →
Catriona Yale (Chief Development Officer) filed 15 Form 4 reports in the past 24 months (0 purchases, 15 sales, 4 filed past the two-business-day deadline), most often in AKRO. The largest single filing was $3.0M of AKRO (53,590 sh across 3 lots, as filed), executed Jan 27 2025.
The name
AKRO
AKRO
AKRO · 63 filings in 24 months
ticker →
Insider filings, newest first→
View the original filing at www.sec.gov→
Other filings by Catriona Yale in AKRO
AKROSALE
Akero Therapeutics, Inc.
$458K8,658 sh × $52.87
Exec Jul 16 2025
Filed Jul 18 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $493K
9,105 sh across 2 lots
Exec Jun 16 2025
Filed Jun 20 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. $151K
2,803 sh × $54.00
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $393K
10,000 sh across 3 lots
Exec May 15 2025
Filed May 19 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $298K
7,873 sh × $37.80
Exec Apr 15 2025
Filed Apr 16 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $367K
8,201 sh × $44.70
Exec Mar 17 2025
Filed Mar 18 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $453K
9,100 sh × $49.79
Exec Feb 18 2025
Filed Feb 21 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. $3.0M
53,590 sh across 3 lots
Exec Jan 27 2025
Filed Jan 31 2025 · 5:30 PM ET †